Rapid microwave-assisted synthesis of ZnMn dual-atom nanozymes for cancer catalytic immunotherapy.

Authors

Qiqi Xu, Qiang Sun, Yanheng Wu, Jinxuan Wang, Shangqin Yang, Hongmei Liu, Lulu Cai

Published in

Biomaterials. Volume 338. Issue Pt A. Pages 124673. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

Catalytic nanomedicines face a persistent trade-off between structurally defined active sites and rapid synthesis. A microwave-assisted salt-flux conversion is developed that transforms a bimetallic metal-organic framework precursor within 3 min into nitrogen-doped carbon-supported ZnMn dual-atom nanozymes (ZnMn DAzymes). Aberration-corrected HAADF-STEM and dual-edge X-ray absorption fine structure analyses support adjacent Zn-Mn sites with an N-dominated ZnMn-N₆-like coordination motif. Steady-state kinetics and density functional theory calculations suggest cooperative catalysis: Zn modulates H₂O₂ adsorption and O-O bond activation, whereas Mn provides stronger H₂O₂ chemisorption and redox flexibility, jointly enhancing catalase-, peroxidase-, and oxidase-like activities. The resulting cascade decomposes H₂O₂, relieves hypoxia, generates reactive oxygen species, and depletes glutathione, inducing mitochondrial dysfunction, immunogenic cell death, cGAS-STING-associated signaling, dendritic-cell maturation, and effector T-cell infiltration. Glutathione-responsive Mn²⁺ release additionally enables activatable T₁-weighted magnetic resonance contrast. Combined with αPD-L1, ZnMn DAzymes suppress primary and distal tumors by approximately 90%, reduce lung metastases by 92%, and prolong survival in 4T1 models. This work provides a rapid route to ZnMn dual-atom nanozymes for catalytic immunotherapy.

PMID:
42828844
Bibliographic data and abstract were imported from PubMed on 04 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.